Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07452198) titled 'A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma' on Feb. 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Condition:
Multiple Myeloma
Intervention:
Drug: GR1803 injection
Drug: Daratumumab
Drug: Pomalidomide
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: March 2026
Target Sample Size: 358
To know mo...